---
title: How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Children,
  Adolescents, and Young Adults
date: '2024-04-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38657263/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240425181115&v=2.18.0.post9+e462414
source: Blood
description: Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL)
  represents a high-risk B-lineage ALL subtype characterized by adverse clinical features
  and poor relapse-free survival despite risk-adapted multi-agent chemotherapy regimens.
  The advent of next-generation sequencing has unraveled the diversity of kinase-activating
  genetic drivers in Ph-like ALL that are potentially amenable to 'personalized' molecularly-targeted
  therapies. Based upon robust preclinical data and ...
disable_comments: true
---
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) represents a high-risk B-lineage ALL subtype characterized by adverse clinical features and poor relapse-free survival despite risk-adapted multi-agent chemotherapy regimens. The advent of next-generation sequencing has unraveled the diversity of kinase-activating genetic drivers in Ph-like ALL that are potentially amenable to 'personalized' molecularly-targeted therapies. Based upon robust preclinical data and ...